Onco Actu du 25 mars 2015

Sommaire 2. Etiologie Consuming three alcoholic drinks a day may cause liver cancer – study [The Guardian] Cancer patients want more info about CT risks [Reuters] 2.6 Etiologie - Environnement Widely used herbicide linked to cancer [Nature News & Comment] Monsanto seeks retraction for report linking herbicide to cancer [Reuters] 3.4.1 Chimioprévention - aspirine Precision Medicine: Who Benefits from Aspirin to Prevent Colorectal Cancer? [NIH Director's Blog] 5. Traitements Our Milestones: A recipe for success - the birth of combination chemotherapy [Cancer Research UK] The Exceptional Responders Initiative: Welcoming More Cases [National Cancer Institute] 5.10 Traitements - Essais The Best Way to Halt a Clinical Trial [In the Pipeline] Merck's Keytruda bests BMS' Yervoy in head-to-head melanoma trial [FiercePharma] Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early [Merck] Merck says melanoma drug meets goal; study halted [Reuters] 5.2 Traitements - Pharma Astellas and Medication Announce New Enzalutamide Data Presented During Plenary Presentations at The 2015 European of Urology Congress [Astellas] Lpath's kidney cancer drug fails mid-stage trial [Reuters] 5.4 Traitements - Economie IPO News: CAR T goes into overdrive: Cellectis increases proposed IPO deal size by 50% [Renaissance Capital] New Patent Law Would Trash Disease Cures [Forbes] 6. Lutte contre les cancers Experts Back Angelina Jolie Pitt in Choices for Cancer Prevention [NY Times] News analysis: Angelina Jolie's surgery to 'cut ovarian cancer risk' [NHS Choices] Angelina Jolie column about surgery heralded by top ovarian cancer doctors [The Guardian] ‘I had a ticking time bomb inside me’: four women who faced Angelina Jolie’s choice [The Guardian] Angelina Jolie and ovarian cancer: the facts about screening and surgery [The Guardian] 6.1 Lutte - Observation Cancer survival rates in UK are a 'shameful' decade behind Europe [The Telegraph] 6.3 Lutte - Associations Cancer Research UK partners with the Engineering and Physical Sciences Research Council to inspire innovation [Cancer Research UK] 6.5 Lutte - Médecines alternatives Dr. Hidaeka Tsuda demonstrates that antineoplastons don’t work against colon cancer [Respectful Insolence] 6.6 Lutte - Publications Authors retract PNAS Epstein-Barr virus paper for "anomalous and duplicated" figures [Retraction Watch at Retraction Watch] 6.7 Lutte - DMP, Big Data & applis Apple isn’t just satisfied reinventing health care, it’s targeting clinical trials as well​ [Singularity HUB] 6.8 Lutte - Communication On Cancer: What Are Exceptional Responders? [Memorial Sloan Kettering Cancer Center]

2. Etiologie Consuming three alcoholic drinks a day may cause liver cancer – study [The Guardian] 25/03/2015 - www.theguardian.com Paul Pharoah, professor of cancer epidemialogy at Cambridge University, cast doubt on the WCRF’s findings. “I do not think that the published data are sufficiently robust to conclude that three drinks a day specifically is associated with an increased risk of primary liver cancer,” he said. Cancer patients want more info about CT risks [Reuters] 24/03/2015 - www.reuters.com “Our findings portray a gap between current practice and what patients say they want.” 2.6 Etiologie - Environnement Widely used herbicide linked to cancer [Nature News & Comment] 25/03/2015 - www.nature.com Guyton strongly defends the IARC process and insists that there is a set of clear rules that lays out which studies can be considered by the experts convened by the IARC. These are broadly limited to peer-reviewed publications and government reports, leading to the rejection of a number of industry-submitted studies. Monsanto seeks retraction for report linking herbicide to cancer [Reuters] 24/03/2015 - www.reuters.com The United States and other international regulatory bodies have backed the safety of glyphosate when used as directed, but the IARC report cited studies that raised concerns about glyphosate and impacts on health. Monsanto says such studies are invalid. But critics say they merit attention. 3.4.1 Chimioprévention - aspirine Precision Medicine: Who Benefits from Aspirin to Prevent Colorectal Cancer? [NIH Director's Blog] 25/03/2015 - directorsblog.nih.gov It still remains to be determined exactly how these uncommon genetic variants and/or nearby sections of DNA offset the properties of aspirin that guard against colorectal cancer in most people. But researchers speculate that it may have something to do with an increased tendency towards inflammation that is for some reason resistant to aspirin’s anti-inflammatory effects. 5. Traitements Our Milestones: A recipe for success - the birth of combination chemotherapy [Cancer Research UK] 25/03/2015 - scienceblog.cancerresearchuk.org In the latest Our Milestones series post, we look at the role we played in the advent of a 1970s cancer treatment revolution: combination chemotherapy. The Exceptional Responders Initiative: Welcoming More Cases [National Cancer Institute] 25/03/2015 - www.cancer.gov Dr. Conley encourages clinical trial investigators to review data from their completed clinical trials and treating oncologists to look back in their patient records to identify potential cases of exceptional responses and submit them for consideration. Clinicians who submit cases also will become part of the analysis team for that case. 5.10 Traitements - Essais The Best Way to Halt a Clinical Trial [In the Pipeline] 25/03/2015 - pipeline.corante.com Couple this with the kinds of data that Bristol-Myers Squibb and others are generating, and PD-1 looks like it's justifying its hype (which has been significant). Merck's Keytruda bests BMS' Yervoy in head-to-head melanoma trial [FiercePharma] 25/03/2015 - www.fiercepharma.com Opdivo's lung cancer nod put Bristol-Myers ahead in that field, at least in squamous non-small cell lung cancer (NSCLC) patients. Keytruda is eying an NSCLC indication as well, and given the data at hand, the Merck med may get an FDA approval covering a broader range of patients. Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early [Merck] 25/03/2015 - www.mercknewsroom.com KEYTRUDA is the first anti-PD-1 therapy to demonstrate a survival advantage compared to the standard of care for the first-line treatment of advanced melanoma. These data will be presented in the opening plenary session at the American Association of Cancer Research (AACR) Annual Meeting in Philadelphia, April 18-22. Merck says melanoma drug meets goal; study halted [Reuters] 24/03/2015 - www.reuters.com The data, if regulators agree, could allow Merck to widen its marketing of Keytruda to people being treated for the first time for the dangerous skin disease. 5.2 Traitements - Pharma Astellas and Medication Announce New Enzalutamide Data Presented During Plenary Presentations at The 2015 European of Urology Congress [Astellas] 25/03/2015 - www.astellas.com The study achieved its primary objective of a statistically significant increase in PFS for enzalutamide compared to bicalutamide. Lpath's kidney cancer drug fails mid-stage trial [Reuters] 24/03/2015 - www.reuters.com Patients taking the drug, Asonep, did not show significant survival rates without the disease worsening. 5.4 Traitements - Economie IPO News: CAR T goes into overdrive: Cellectis increases proposed IPO deal size by 50% [Renaissance Capital] 25/03/2015 - www.renaissancecapital.com The Paris, France-based company now plans to offer 4.75 million shares. At its Monday trading price on the Euronext Paris of $41.41, Cellectis would raise $197 million, or 53% more than previously anticipated New Patent Law Would Trash Disease Cures [Forbes] 25/03/2015 - www.forbes.com In short, the new law is designed to give giant companies even more power, and small companies less opportunity to receive funding from investors and corporate partners. 6. Lutte contre les cancers Experts Back Angelina Jolie Pitt in Choices for Cancer Prevention [NY Times] 25/03/2015 - www.nytimes.com Ms. Jolie Pitt’s decision not to remove her uterus was consistent with what experts recommended. “There is no research showing that having a BRCA mutation puts women at risk for uterine cancer,” said Dr. Jamie Bakkum-Gamez, a gynecologic oncologist at the Mayo Clinic. News analysis: Angelina Jolie's surgery to 'cut ovarian cancer risk' [NHS Choices] 25/03/2015 - www.nhs.uk Having a family history of ovarian cancer, especially if the cancer developed before the age of 50, could mean the faulty genes run in your family. Angelina Jolie column about surgery heralded by top ovarian cancer doctors [The Guardian] 24/03/2015 - www.theguardian.com Dr Karen Liu, chair of gynecologic oncology at University of Texas’s MD Anderson Cancer Center, said that Jolie’s piece was also important because it illustrated the “emotional rollercoaster” women faced when considering having the procedure. ‘I had a ticking time bomb inside me’: four women who faced Angelina Jolie’s choice [The Guardian] 24/03/2015 - www.theguardian.com Here are four accounts of women who have elected to have their ovaries removed, for differing reasons, and with differing effects. Angelina Jolie and ovarian cancer: the facts about screening and surgery [The Guardian] 24/03/2015 - www.theguardian.com Carrying a faulty version of BRCA1 (as Jolie does) translates to a roughly 39% chance of developing ovarian cancer sometime during your life, compared with 1.4% for the general population. 6.1 Lutte - Observation Cancer survival rates in UK are a 'shameful' decade behind Europe [The Telegraph] 24/03/2015 - www.telegraph.co.uk “What we can see here is that better cancer survival rates are not unachievable. If countries like Sweden, France, Finland and Austria can achieve these rates, then the UK can and should, bridge the gap." 6.3 Lutte - Associations Cancer Research UK partners with the Engineering and Physical Sciences Research Council to inspire innovation [Cancer Research UK] 25/03/2015 - www.cancerresearchuk.org The new partnership increases the amount of funding for collaborative research to up to £37.5 million over five years. 6.5 Lutte - Médecines alternatives Dr. Hidaeka Tsuda demonstrates that antineoplastons don’t work against colon cancer [Respectful Insolence] 25/03/2015 - scienceblogs.com The very data presented show that ANPs are not useful as an adjuvant therapy for successfully resected colorectal cancer metastases. Again, this is a negative trial. 6.6 Lutte - Publications Authors retract PNAS Epstein-Barr virus paper for "anomalous and duplicated" figures [Retraction Watch at Retraction Watch] 25/03/2015 - retractionwatch.com PNAS has retracted a paper on the cancer-causing Epstein-Barr virus just two months after publication, in a notice that fingers a now-former graduate student for manipulating figures. 6.7 Lutte - DMP, Big Data & applis Apple isn’t just satisfied reinventing health care, it’s targeting clinical trials as well​ [Singularity HUB] 25/03/2015 - singularityhub.com Apple’s recent announcement of ResearchKit shows that it has an even greater ambition: It wants to also transform the pharmaceutical industry by changing the way clinical trials are done. 6.8 Lutte - Communication On Cancer: What Are Exceptional Responders? [Memorial Sloan Kettering Cancer Center] 25/03/2015 - www.mskcc.org This blog post is part of a series we’re running in anticipation of the upcoming documentary, Cancer: The Emperor of All Maladies, presented by Ken Burns, which begins airing March 30 on PBS.